Photo from wikipedia
Entrectinib may be an effective therapy for patients with NTRK fusion-positive solid tumors, regardless of tumor type. In a combined analysis of phase I and phase II trials, more than… Click to show full abstract
Entrectinib may be an effective therapy for patients with NTRK fusion-positive solid tumors, regardless of tumor type. In a combined analysis of phase I and phase II trials, more than half of patients responded to the drug, with a similar response rate in patients whose cancer had spread to the brain.
Keywords:
fusion positive;
across ntrk;
entrectinib effective;
ntrk fusion;
effective across
Journal Title: Cancer discovery
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!